Dermatology NewsTreatment with Tildrakizumab Effective for Scalp Psoriasis in Phase 3b StudyJanuary 14, 2025PsoriasisPsoriatic Arthritis
Dermatology NewsNew Ideas on PsA Pathogenesis May Drive New TreatmentsJanuary 8, 2025Psoriatic Arthritis
Dermatology NewsCardiac Risks of Newer Psoriasis Biologics vs. TNF Inhibitors ComparedJanuary 7, 2025PsoriasisPsoriatic Arthritis
Dermatology NewsCombined Clinics, Personalized Medicine for Psoriatic Disease Face BarriersJanuary 2, 2025Psoriatic ArthritisPsoriasis
Dermatology NewsFDA Approves Ustekinumab Biosimilar Steqeyma, the Seventh of Its KindDecember 19, 2024Psoriatic ArthritisPsoriasis
Dermatology NewsAdalimumab for Psoriasis: Study Compares Biosimilars Vs. OriginatorDecember 2, 2024PsoriasisPsoriatic Arthritis
Dermatology NewsUpdated Guidance for Psoriatic Arthritis Ultrasound Comes at Time of Growing Use, New TechnologyNovember 18, 2024Psoriatic ArthritisPsoriasis
Dermatology NewsStudy Supports Efficacy of Home-Based Phototherapy for PsoriasisOctober 3, 2024PsoriasisPsoriatic Arthritis
Dermatology NewsBimekizumab Gains FDA Approval for Psoriatic Arthritis, Axial SpondyloarthritisSeptember 24, 2024Psoriatic ArthritisPsoriasis
Dermatology NewsTopical Tapinarof and Roflumilast for Psoriasis: Where Do they Fit In?September 10, 2024PsoriasisPsoriatic Arthritis
Dermatology NewsUstekinumab’s ‘Egregious’ Medicare Part B and D Pricing Differences Led to Federal InterventionAugust 30, 2024Business of MedicinePsoriatic ArthritisPsoriasis
Dermatology NewsNew Associations Identified Between IBD and Extraintestinal ManifestationsAugust 29, 2024Psoriatic Arthritis
Dermatology NewsTYK2 Inhibitor Effective for Psoriasis in Phase 2 StudyAugust 27, 2024PsoriasisPsoriatic Arthritis
Dermatology NewsPatients With Immune-Mediated Inflammatory Diseases, Type 2 Diabetes Reap GLP-1 Receptor Agonist Benefits, TooAugust 23, 2024Psoriatic ArthritisPsoriasisAutoimmune Diseases
